Ladenburg Thalmann Reiterates Nile Therapeutics Buy, $4 PT

Symbols: NLTX
Share

Ladenburg Thalmann reiterated its Nile Therapeutics (NASDAQ: NLTX) Buy rating and $4 price target in a research report published today.


 
 
< Previous
Oppenheimer Reiterates Perform Rating on Ski-Mobi
Next >
Wunderlich Securities Maintains Buy Rating and $75 PT on Home Properties
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust